This article is over a month old and may contain outdated advice from the authorities regarding coronary heart disease.
Stay up to date in NRK’s overview, or through FHIs nettsider.
–
In a press release The National Board of Health states that one death has been registered in connection with this vaccine.
In light of this, European health authorities have launched investigations into the vaccine.
Be prepared
The National Board of Health emphasizes that they cannot yet establish that people have had a blood clot or died as a result of the vaccine.
– It is well documented that the vaccine is both safe and effective. But both we and the Danish Medicines Agency have to react to reports of possible serious side effects, both from Denmark and other European countries. This shows that the monitoring system works, says director of the National Board of Health Søren Brostrøm in the press release.
The National Board of Health corresponds to the National Institute of Public Health (NIPH) in Norway.
Prime Minister Mette Frederiksen tells the Danish news agency Ritzau that she received the news with annoyance.
– It is too early to say what the significance of this will be, says Frederiksen.
– Dramatically
Steinar Madsen, medical director at the Norwegian Medicines Agency, says that so far there have been no reports of blood clots in connection with the use of the vaccine in Norway.
– It worries me, because it’s quite dramatic. However, blood clots have been reported in connection with this vaccine from several countries. We are also aware of that in Norway, says Madsen to NRK.
The Norwegian Medicines Agency will now familiarize itself with the results and assess what is being done on the Norwegian side.
– We have so far not received any side effects reports of this type in Norway, but we will of course be very aware of this in the future.
– Should the vaccination with AstraZeneca then continue as normal in this country?
– We must have time to think about it a bit and discuss with FHI, says Madsen.
Now at 11 o’clock, FHI will meet with the Norwegian Medicines Agency to discuss the situation, NRK is informed.
Urgent meeting
NRK has been in contact with FHI, but has not yet received an answer on how this information is assessed in Norway.
Norwegian health authorities have been aware of the reports of blood clots for some time.
In the past, Austria has also withheld a vaccine supply of one million doses due to reports of blood clots.
The current delivery is marked ABV5300 and has been delivered to 17 countries, but not to Norway.
The Austrian authorities have so far not concluded that there is a link between the vaccine and the cases of blood clots.
Earlier this week, the Norwegian health authorities decided that the vaccine from AstraZeneca should also be given to people over 65 years of age.
Until now, health personnel and people under the age of 65 have been offered the vaccine in Norway.
–
